- Azenta posted Q1 2025 revenue of $147.51 million, up 4% year-over-year, with non-GAAP gross margin of 47.6% and adjusted EBITDA margin of 9.0% (both up meaningfully versus year-ago levels). Management highlighted the ongoing transformation agenda and portfolio optimization as catalysts for profitability and long-term value. A notable strategic development is the sale of B Medical Systems, now reported in discontinued operations, allowing Azenta to streamline its portfolio and reallocate capital to higher-return opportunities.
- The SMS and Multiomics axes delivered solid quarterly performance amid a cautious market backdrop. NGS volume and Plasmid-EZ momentum supported health in Multiomics, while SMS benefited from growth in Consumables, Instruments, Core Products and sample storage. Free cash flow reached $22 million, contributing to a robust liquidity stance with approximately $503 million in cash and equivalents excluding discontinued operations and no current debt.
- Management reaffirmed 2025 guidance of 3–5% organic revenue growth and roughly 300bp of adjusted EBITDA margin expansion for the year, underscoring progress from cost optimization, operating-model improvements, and a disciplined capital-allocation framework. The company outlined a staged path to profitability through portfolio simplification, Kaizen-driven efficiency programs, and a shift toward a two-operating-company structure, with continued emphasis on revenue quality, on-time delivery, and working-capital discipline.